Abstract
PurposeWhile the overall impact of chronic rhinosinusitis (CRS) on patients’ health is diverse, many affected individuals have a substantially impaired quality of life (QoL). The aim of this study was to evaluate the impact of sex-associated differences specifically in the subgroups of CRS with nasal polyps (CRSwNP) and aspirin-exacerbated respiratory disease (AERD) by assessing QoL parameters in women and men separately.MethodsIn a retrospective single-center study, 59 patients with CRSwNP (39 males and 20 females) and 46 patients with AERD (18 males and 28 females) were included. Patient-reported outcome measures (PROM) evaluating QoL via the Sino-Nasal Outcome Test-20 German Adapted Version (SNOT-20 GAV) as well as the total polyp score (TPS) were analysed.ResultsThere was no significant difference in TPS (p = 0.5550) and total SNOT-20 GAV scores (p = 0.0726) between male or female patients with CRSwNP or AERD. Furthermore, no significant sex differences were found within disease groups regarding the subcategories of the SNOT-20 GAV items.ConclusionThus, quality of life is severely impaired in patients suffering from various forms of CRS regardless of their sex.
Highlights
Sex- and gender-related factors are present in a variety of diseases affecting the clinical presentation and treatment of these medical conditions, as well as the impact on patients’ quality of life (QoL) [1]
CRS with nasal polyps (CRSwNP) affects between 2.7 and 4.4% of the population and approximately 10% of these patients with nasal polyps suffer from aspirin-exacerbated respiratory disease (AERD) syndrome, which is characterized by the clinical triad of nasal polyps, bronchial asthma, and hypersensitivity to non-steroidal antiinflammatory drugs (NSAIDs) [6,7,8]
We focused on the comparison of patients suffering from Chronic rhinosinusitis (CRS) presenting with nasal polyps (CRSwNP) alone and those diagnosed with AERD
Summary
Sex- and gender-related factors are present in a variety of diseases affecting the clinical presentation and treatment of these medical conditions, as well as the impact on patients’ quality of life (QoL) [1]. According to the recently published current version of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020), the condition should be classified into primary and secondary CRS. While the former is associated with generalized inflammation, the latter is caused by other underlying triggers including tumours, odontogenic reasons, or fungal growth. CRSwNP affects between 2.7 and 4.4% of the population and approximately 10% of these patients with nasal polyps suffer from aspirin-exacerbated respiratory disease (AERD) syndrome, which is characterized by the clinical triad of nasal polyps, bronchial asthma, and hypersensitivity to non-steroidal antiinflammatory drugs (NSAIDs) [6,7,8]. CRSwNP and AERD generate nasal symptoms and impair quality of sleep, mood, cognition, and productivity [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
